- Home
- CSTL vs NAT Comparison
CSTL vs NAT Comparison
Compare CSTL & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- NAT
- Stock Information
- Founded
- CSTL 2007
- NAT 1995
- Country
- CSTL United States
- NAT Bermuda
- Employees
- CSTL N/A
- NAT N/A
- Industry
- CSTL Medical Specialities
- NAT Marine Transportation
- Sector
- CSTL Health Care
- NAT Consumer Discretionary
- Exchange
- CSTL Nasdaq
- NAT Nasdaq
- Market Cap
- CSTL 555.8M
- NAT 603.5M
- IPO Year
- CSTL 2019
- NAT 1997
- Fundamental
- Price
- CSTL $24.21
- NAT $3.12
- Analyst Decision
- CSTL Strong Buy
- NAT Hold
- Analyst Count
- CSTL 6
- NAT 2
- Target Price
- CSTL $37.67
- NAT $3.50
- AVG Volume (30 Days)
- CSTL 712.7K
- NAT 1.8M
- Earning Date
- CSTL 08-04-2025
- NAT 08-28-2025
- Dividend Yield
- CSTL N/A
- NAT 10.91%
- EPS Growth
- CSTL N/A
- NAT N/A
- EPS
- CSTL N/A
- NAT 0.06
- Revenue
- CSTL $346,269,000.00
- NAT $301,169,000.00
- Revenue This Year
- CSTL N/A
- NAT N/A
- Revenue Next Year
- CSTL N/A
- NAT $6.07
- P/E Ratio
- CSTL N/A
- NAT $50.92
- Revenue Growth
- CSTL 20.40
- NAT N/A
- 52 Week Low
- CSTL $14.59
- NAT $2.13
- 52 Week High
- CSTL $35.84
- NAT $3.83
- Technical
- Relative Strength Index (RSI)
- CSTL 76.51
- NAT 65.81
- Support Level
- CSTL $20.35
- NAT $2.96
- Resistance Level
- CSTL $20.80
- NAT $3.07
- Average True Range (ATR)
- CSTL 0.95
- NAT 0.08
- MACD
- CSTL 0.45
- NAT 0.02
- Stochastic Oscillator
- CSTL 96.67
- NAT 92.42
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.